Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2020

Jan 19, 2021

SELL
$7.75 - $11.42 $3,100 - $4,568
-400 Closed
0 $0
Q3 2020

Oct 09, 2020

BUY
$9.38 - $11.76 $3,752 - $4,704
400 New
400 $4,000

Others Institutions Holding MTCR

# of Institutions
1
Shares Held
0
Call Options Held
0
Put Options Held
0

About Metacrine, Inc.


  • Ticker MTCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,569,500
  • Description
  • Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
More about MTCR
Track This Portfolio

Track Fny Investment Advisers, LLC Portfolio

Follow Fny Investment Advisers, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fny Investment Advisers, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fny Investment Advisers, LLC with notifications on news.